Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies

Wednesday, July 2, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH EASTON, Mass., July 1 PressureBioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists fromthe New York University ("NYU") School of Medicine and the Brooklyn HospitalCenter presented results yesterday on advances they made in the areas ofbreast and colon cancer, stroke, and in vitro fertilization ("IVF"). Theresults were generated in studies using PBI's patented pressure cyclingtechnology ("PCT") and patent-pending PCT-dependent ProteoSolve-LRS proteinextraction kit. The presentations were made at the 2nd Annual Advances inBiomolecular Engineering: Protein Design Symposium, sponsored by the New YorkAcademy of Sciences.

Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology)and principle investigator for the research studies, commented: "PCT iscritical to our work. This novel, cutting-edge technology consistently givesus rapid and reliable extraction of proteins from our important samples. Inaddition -- and this is very exciting -- PCT has given us the additionalextraordinary benefits of not only greater protein yield, but the extractionof proteins not previously identified in these types of samples. Consequently,we believe that the use of PCT, more than the use of any extraction technologyavailable today, could lead to the discovery of new biomarkers for cancer andstroke, which in turn could lead to the development of new diagnostics andtherapeutics to combat these diseases."

Dr. Pevsner continued: "Many IVF live births result in twins, triplets,and higher order births. Unfortunately, fetuses and mothers of multiple andhigh-order multiple pregnancies have increased morbidity and mortality. Tocombat this, more single embryo transfers are needed. To this end, we havebeen interested in identifying biomarkers for embryo viability and competence.Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth mediaonly seen in competent embryos. These proteins may prove to be biomarkers thatcan enhance selection and result in more live births from single embryotransfers. These are very exciting results."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused onthe development of a novel, enabling technology called Pressure CyclingTechnology (PCT). PCT uses cycles of hydrostatic pressure between ambient andultra-high levels (up to 35,000 psi and higher) to control bio-molecularinteractions. PBI currently holds 13 US and 6 foreign patents coveringmultiple applications of PCT in the life sciences field, including such areasas genomic and proteomic sample preparation, pathogen inactivation, thecontrol of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company'sintentions, hopes, beliefs, expectations, or predictions of the future are"forward-looking'' statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements include the reportedeffectiveness of PCT to extract new proteins; the speed of sample preparationusing PCT compared with other sample preparation methods; the importance ofProteoSolve-LRS and PCT in the reported identification of new proteins incancer, stroke, and IVF samples; and the possibility that extraction ofproteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies,diagnostic paradigms, and enhanced selection for single embryo transfers.These statements are based upon the Company's current expectations, forecasts,and assumptions that are subject to risks, uncertainties, and other factorsthat could cause actual outcomes and results to differ materially from thoseindicated by these forward-looking statements. These risks, uncertainties, andother factors include, but are not limited to: unforeseen technologicaldifficulties that the Company may encounter in the development of P

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store